(Stroke. 1996;27:593-598.)
© 1996 American Heart Association, Inc.
Articles |
Nimodipine Neuroprotection in Cardiac Valve Replacement
Report of an Early Terminated Trial
From the Department of Public Health Sciences (C.L., C.D.F., L.E.W.), Department of Anesthesia (A.T.R., D.A.S.), Department of Neurology (L.C., B.T.T.), and Division of Surgical Sciences (J.W.H.), Bowman Gray School of Medicine, Winston-Salem, NC.
Correspondence to Dr C. Legault, Department of Public Health Sciences, Bowman Gray School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1063. E-mail Legault@phs.bgsm.wfu.edu.
Background We conducted a double-blind, randomized clinical trial in patients undergoing cardiac valve replacement to determine whether nimodipine, a dihydropyridine calcium antagonist, reduced the risk of new neurological, neuro-ophthalmologic, or neuropsychological deficits—common complications associated with cardiac surgery—1 week after surgery.
Methods and Results Enrollment for a total of 400 patients started in May 1992 and was stopped in September 1994, with 150 patients randomized to the study. Nimodipine was given to the patients during the perioperative period. Patients underwent examinations before surgery and at approximately 1 week, 1 month, and 6 months after surgery. Major adverse events, including deaths and strokes, were monitored monthly. The trial was terminated early because of both an unexpected disparity in death rates between groups and a lack of evidence of a beneficial effect of nimodipine. New deficits were observed in 72% of the placebo group versus 77% of the nimodipine group (P=.55). In the 6-month follow-up period, 8 deaths (10.7%) occurred in the nimodipine group (n=75) compared with 1 death (1.3%) in the placebo group (n=74) (P=.02). Major bleeding occurred in 10 patients in the nimodipine group versus 3 in the placebo group (13.3% versus 4.1%; P=.04). Six (46.2%) of the 13 patients with major bleeding died compared with 3 deaths (2.2%) among the 136 patients without major bleeding.
Conclusions Our findings add to the growing evidence that calcium antagonists have a prohemorrhagic effect in some patients and suggest that nimodipine use should be restricted perioperatively in patients scheduled for cardiac valve replacement.
Key Words: hemorrhage • nimodipine • complications • calcium channel blockers
This article has been cited by other articles:
 |
|
 |
|
  Y. Kadoi Pharmacological Neuroprotection During Cardiac Surgery Asian Cardiovasc Thorac Ann, April 1, 2007; 15(2): 167 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Dorotta, P. Kimball-Jones, and R. Applegate II Deep hypothermia and circulatory arrest in adults. Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2007; 11(1): 66 - 76. [Abstract] [PDF]
|
|
|
|
 |
|
 C. W. Hogue Jr, C. A. Palin, and J. E. Arrowsmith Cardiopulmonary bypass management and neurologic outcomes: an evidence-based appraisal of current practices. Anesth. Analg., July 1, 2006; 103(1): 21 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Butterworth, L. E. Wagenknecht, C. Legault, D. J. Zaccaro, N. D. Kon, J. W. Hammon Jr, A. T. Rogers, B. T. Troost, D. A. Stump, C. D. Furberg, et al. Attempted control of hyperglycemia during cardiopulmonary bypass fails to improve neurologic or neurobehavioral outcomes in patients without diabetes mellitus undergoing coronary artery bypass grafting J. Thorac. Cardiovasc. Surg., November 1, 2005; 130(5): 1319 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Prasongsukarn and M. A. Borger Reducing Cerebral Emboli During Cardiopulmonary Bypass Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2005; 9(2): 153 - 158. [Abstract] [PDF]
|
|
|
|
|
|
D. N. Wijeysundera, W. S. Beattie, V. Rao, J. Ivanov, and K. Karkouti Calcium antagonists are associated with reduced mortality after cardiac surgery: a propensity analysis J. Thorac. Cardiovasc. Surg., March 1, 2004; 127(3): 755 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Wijeysundera, W. S. Beattie, V. Rao, and J. Karski Calcium antagonists reduce cardiovascular complications after cardiac surgery: A meta-analysis J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1496 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Butterworth and J. W. Hammon Lidocaine for Neuroprotection: More Evidence of Efficacy Anesth. Analg., November 1, 2002; 95(5): 1131 - 1133. [Full Text] [PDF]
|
|
|
|
|
|
D. Wang, X. Wu, J. Li, F. Xiao, X. Liu, and M. Meng The Effect of Lidocaine on Early Postoperative Cognitive Dysfunction After Coronary Artery Bypass Surgery Anesth. Analg., November 1, 2002; 95(5): 1134 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D C Whitaker, J Stygall, and S P Newman Neuroprotection during cardiac surgery: strategies to reduce cognitive decline Perfusion, March 1, 2002; 17(2_suppl): 69 - 75. [Abstract] [PDF]
|
|
|
|
 |
|
 J. M. Murkin Attenuation of neurologic injury during cardiac surgery Ann. Thorac. Surg., November 1, 2001; 72(5): S1838 - 1844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Kizer and S. E. Kimmel Epidemiologic Review of the Calcium Channel Blocker Drugs: An Up-to-date Perspective on the Proposed Hazards Arch Intern Med, May 14, 2001; 161(9): 1145 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Neville, J. Butterworth, R. L. James, J. W. Hammon, and D. A. Stump Similar neurobehavioral outcome after valve or coronary artery operations despite differing carotid embolic counts J. Thorac. Cardiovasc. Surg., January 1, 2001; 121(1): 0125 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Garcia Rodriguez, C. Cattaruzzi, M. G. Troncon, and L. Agostinis Risk of Hospitalization for Upper Gastrointestinal Tract Bleeding Associated With Ketorolac, Other Nonsteroidal Anti-inflammatory Drugs, Calcium Antagonists, and Other Antihypertensive Drugs Arch Intern Med, January 12, 1998; 158(1): 33 - 39. [Abstract] [Full Text] [PDF]
|
|